An interventional study of High-flow nasal cannula and Conventional nasal cannula in Congenital Heart Disease and High Flow Nasal Canula, sponsored by Fu Jen Catholic University. Not yet recruiting at 2 sites in Taiwan. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Fu Jen Catholic University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Heart Defects, Congenital with a site in Taiwan — 2 open to participants now, 4 under way, none of them phase 3. Heart Defects, Congenital · Taiwan.
Among the 12 studies in Heart Defects, Congenital with a site in Taiwan, this one is one of 2 that started in 2026, is one of 6 with no phase, and was the 12th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.
Browse Heart Defects, Congenital studies →2 of the 12 studies in Heart Defects, Congenital with a site in Taiwan are open now. Recruiting first, the newest first:
Chi-Wen Chen · Sites in Taiwan
Ages 12–18
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 60 across 507 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 120 across the 9 interventional studies, 4,000 across the 3 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
Fu Jen Catholic University is the lead sponsor of 48 studies on the registry; 22 are open to participants now.
Fu Jen Catholic University has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Defects, Congenital with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872320Chang Gung Memorial HospitalThe Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease | 2026-12-31 |
| NCT07937579Fu Jen Catholic UniversityEfficacy and Safety of High-Flow Nasal Cannula During Transcatheter Closure Procedures | 2027-07-31 |
| NCT06719323Chi-Wen ChenLong-term Effects of Family WISH Program for Adolescents With Congenital Heart Disease | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Heart Defects, Congenital with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of high-flow nasal cannula oxygen therapy, compared with standard nasal cannula oxygen therapy, as respiratory support during transcatheter closure procedures for congenital heart disease under non-intubated deep sedation.
Transcatheter closure is a standard treatment for selected congenital heart diseases and is often performed under deep sedation with transesophageal echocardiographic guidance. During non-intubated sedation, oxygen desaturation may occur due to airway collapse, respiratory depression, supine positioning, or limited cardiopulmonary reserve. Standard nasal cannula oxygen may be insufficient in high-risk patients, whereas HFNC provides heated, humidified high-flow oxygen, stable FiO2, dead-space washout, and mild positive airway pressure to improve oxygenation and airway stability. This study will enroll pediatric and adult patients undergoing transcatheter closure for congenital heart disease. Participants will be stratified by age and/or clinical risk and randomized to receive either HFNC or standard nasal cannula oxygen therapy. This study is expected to clarify whether HFNC can reduce intra-procedural oxygen desaturation, improve oxygenation stability, decrease emergency airway interventions, and maintain hemodynamic safety during deep sedation. The findings may support standardized respiratory support protocols in cardiac catheterization laboratories and provide evidence for individualized peri-procedural care in pediatric and adult congenital heart disease patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive high-flow nasal cannula during transcatheter closure procedures under deep sedation
Device: High-flow nasal cannula
Receive conventional nasal cannula oxygen therapy during transcatheter closure procedures under deep sedation
Device: Conventional nasal cannula
Heated, humidified high-flow oxygen will be delivered through a nasal cannula.
Oxygen will be delivered through a nasal cannula.
Incidence of hypoxemia
Defined as at least one episode of peripheral oxygen saturation below 90% lasting at least 10 seconds
Time frame: From initiation of the assigned oxygen therapy to completion of transcatheter closure procedure
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.
Of 205 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 7 months is below that.
Counting every sponsor, half of 223 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fu Jen Catholic University